Mesoblast (MESO) Consolidated Net Income (2014 - 2023)

Mesoblast (MESO) posted Consolidated Net Income of -$21.9 million for Q2 2023, down 18.14% sequentially from -$18.6 million in Q1 2023, and down 2.41% YoY from -$22.5 million in Q2 2022.

Mesoblast (MESO) Consolidated Net Income (2014 - 2023) Analysis & Trends

Mesoblast has reported Consolidated Net Income for 10 years, with the latest figure at -$21.9 million in Q2 2023.

  • Quarterly Consolidated Net Income fell 2.41% year-over-year to -$21.9 million in Q2 2023, while the trailing twelve-month figure through Dec 2024 was -$21.9 million (up 66.22% YoY) and the FY2025 annual result came in at -$102.1 million, down 16.13% from the prior year.
  • Consolidated Net Income eased to -$21.9 million in Q2 2023 per MESO's latest filing, from -$18.6 million in the prior quarter.
  • Over five years, Consolidated Net Income peaked at -$3.6 million in Q3 2019 and troughed at -$29.4 million in Q2 2020.
  • A 5-year average of -$21.1 million and a median of -$22.2 million in 2019 frame the typical range for Consolidated Net Income.
  • The sharpest annual moves came in 2019 and 2020: Consolidated Net Income jumped 81.09% in 2019, then plunged 570.44% in 2020.
  • Over 5 years, Consolidated Net Income stood at -$22.3 million in 2019, then decreased by 15.46% to -$25.8 million in 2020, then slipped by 0.38% to -$25.9 million in 2021, then increased by 5.61% to -$24.4 million in 2022, then gained by 10.22% to -$21.9 million in 2023.
  • According to Business Quant data, Consolidated Net Income over the past three periods registered -$21.9 million, -$18.6 million, and -$24.4 million for Q2 2023, Q1 2023, and Q4 2022 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Consol Net Inc. (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 482.00 Mn
4 Revolution Medicines 43.64 Bn 43.64 Bn - -644.37 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 237.01 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 930.12
7 Royalty Pharma 33.72 Bn 35.84 Bn - 81.49 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 164.49 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -13.27 Mn
10 Mesoblast 2.01 Bn 1.87 Bn - -

Historic Data

Download Data
DateValue
Jun 30, 2023 -21.92 Mn
Mar 31, 2023 -18.55 Mn
Dec 31, 2022 -24.42 Mn
Sep 30, 2022 -16.83 Mn
Jun 30, 2022 -21.40 Mn
Mar 31, 2022 -21.26 Mn
Dec 31, 2021 -25.87 Mn
Sep 30, 2021 -22.58 Mn
Jun 30, 2021 -22.00 Mn
Mar 31, 2021 -26.42 Mn
Dec 31, 2020 -25.77 Mn
Sep 30, 2020 -23.81 Mn
Jun 30, 2020 -29.35 Mn
Mar 31, 2020 -13.31 Mn
Dec 31, 2019 -22.32 Mn
Sep 30, 2019 -3.55 Mn
Jun 30, 2019 -17.55 Mn
Mar 31, 2019 -22.77 Mn
Dec 31, 2018 -21.74 Mn
Sep 30, 2018 -18.79 Mn